Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: A 90-day multi-center study

https://doi.org/10.1016/0002-9343(86)90468-7Get rights and content

Abstract

The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 non-atopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.

References (53)

  • PP Van Arsdel et al.

    Evaluation of oral fenoterol in chronic asthmatic patients

    Chest

    (1978)
  • BV Branscomb

    Efficacy and side effects of fenoterol compared with isoproterenol administered by metered dose inhaler in asthma

    Chest

    (1978)
  • S Larsson et al.

    Lack of bronchial betaadrenoceptor resistance in asthmatics during long-term treatment with terbutaline

    J Allergy Clin Immunol

    (1977)
  • AF Wilson et al.

    Cardiopulmonary effects of long-term bronchodilator administration

    J Allergy Clin Immunol

    (1976)
  • ME Conolly et al.

    Selective subsensitization of beta-adrenergic receptors in central airways of asthmatics and normal subjects during long-term therapy with inhaled salbutamol

    J Allergy Clin Immunol

    (1982)
  • NJ Gross et al.

    Anticholinergic, antimuscarinic bronchodilators

    Am Rev Respir Dis

    (1984)
  • SW Clarke et al.

    Therapeutic aerosols 2-drugs available by the inhaled route (editorial)

    Thorax

    (1984)
  • RA Francis et al.

    The effect of Sch 1000 MDI on the mucociliary clearance and lung function of healthy volunteers (abstr)

    Postgrad Med J

    (1975)
  • E Krieger et al.

    Sputum rheology following treatment with Sch 1000 MDI and orciprenaline MDI (abstr)

    Postgrad Med J

    (1975)
  • H Matthys et al.

    Quantitative and selective bronchial clearance studies using 99mTc-sulfate particles

    Scand J Respir Dis

    (1974)
  • CS May et al.

    Effect of aerosol ipratropium bromide (Sch 1000) on sputum viscosity and volume in chronic bronchitis (letter)

    Br J Clin Pharmacol

    (1977)
  • E Puchelle et al.

    Sputum viscoelasticity following administration of SCH 1000 MDI (abstr)

    Postgrad Med J

    (1975)
  • VE Stresemann

    Ipratropiumbromid in der kontrollierten Klinischen Prufung

  • A Ahonen et al.

    Bronchodilator action of two different doses of ipratropium bromide (Sch 1000) compared with fenoterol and placebo

    Curr Ther Res

    (1978)
  • WT Ulmer et al.

    Anticholinergika als Bronchodilatatoren

    Arzneimittelforsch

    (1973)
  • LE Klock et al.

    A comparative study of atropine sulfate and isoproterenol hydrochloride in chronic bronchitis

    Am Rev Respir Dis

    (1975)
  • Cited by (135)

    • Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

      2015, Chest
      Citation Excerpt :

      There was a small increase in prebronchodilator FVC and a postbronchodilator increase in the FVC area under the curve over 8 h, and this approached statistical significance. These data suggest that the beneficial effects of a short-acting muscarinic antagonist over short-acting β2-agonist are small in terms of lung function.154–160 There was no study evaluating exacerbation as a primary end point.

    • Anticholinergic Therapies

      2014, Middleton's Allergy: Principles and Practice: Eighth Edition
    • Management of respiratory diseases

      2013, Tidy's Physiotherapy: Fifteenth Edition
    • Acute Exacerbations of Chronic Obstructive Pulmonary Disease in the Emergency Department

      2012, Emergency Medicine Clinics of North America
      Citation Excerpt :

      There is some thought that anticholinergic agents may be superior to β2-agonists to treat the reversible component of COPD based on disease pathophysiology and on anticholinergic mechanism of action. This may be the case in stable COPD.82 In AECOPD, the evidence does not favor one over the other.

    • Clinical Testing of Aerosol Drugs

      2018, Respiratory Drug Delivery
    View all citing articles on Scopus

    Authors' affiliations are listed at the end of this article.

    View full text